	Gareth Morgan, MD, PhD, the director of the Myeloma Institute at the University of Arkansas, discusses his expectations of multiple myeloma treatment going forward.

	 He advocates the investigation of unique treatment plans specifically targeted for each patient population. In the next one or two years, Morgan predicts that oncologists treating multiple myeloma will first do a sequence analysis to determine an individualized treatment based on the pattern of mutations seen in that patient. 

	 His research has found that 50% of all the mutations within myeloma are actionable.

Videos

Gareth Morgan, MD, PhD, the director of the Myeloma Institute at the University of Arkansas, discusses his expectations of multiple myeloma treatment going forward.

Gareth Morgan

Articles

Dr. Morgan on the Future of Myeloma Treatment